IndraLab

Statements

reach
"Together, these results suggest that : (i) the NLRP3 inflammasome and local IL-1beta (+) F4/80 (+) Ly6C (+) macrophages as novel players in the pathogenesis of VCP associated myopathy; and (ii) identified the sulfonylurea MCC950 inhibitor of the NLRP3 inflammasome with promising therapeutic potential for the future treatment of patients with VCP associated myopathy."
27730320
reach
"While Lamkanfi et al clearly showed this drug directly inhibits NLRP3, it is also a widely used sulfonylurea drug for the treatment of type 2 diabetes where it acts at ATP-sensitive K (KATP) channels and Kir6.2."
32602164
reach
"Agarwal et al. (2020) reported that thiazolo-alkenyl sulfonylurea derivative 7 inhibited the activation of NLRP3 by inhibiting ASC oligomerisation (Agarwal, Pethani, et al., 2020)."
34053242
reach
"NOD2 stimulation by systemic administration of muramyl dipeptide appears to be beneficial in mouse models of colitis.123 Glyburide (glibenclamide), a sulfonylurea drug for the treatment of type 2 diabetes, is known to inhibit ATP-sensitive K+ channels and thus can prevent NLRP3 inflammasome activation.124 Glyburide has been shown to prevent ventilator-induced lung injury in mice and delay endotoxin-induced lethality in mice, but it has not been applied for animal models of colitis.124, 125PRR signaling has significant roles in intestinal homeostasis, which is mainly composed of the maintenance of commensals."
23515136
reach
"Glyburide (glibenclamide), a sulfonylurea drug for the treatment of type 2 diabetes, is known to inhibit ATP sensitive K+ channels and thus can prevent NLRP3 inflammasome activation."
23515136
reach
"Glyburide, the most widely used sulfonylurea drug for type 2 diabetes in the US, inhibits the Nalp3 inflammasome."
22065079
reach
"The mechanism by which sulfonylurea compounds inhibit NLRP3 activation is currently not understood."
27508077
reach
"However, unlike for CY-09, the molecular target and mechanism by which MCC950 and CRID3 and related sulfonylurea molecules inhibit the NLRP3 inflammasome remains enigmatic."
29061692
reach
"As evidence showed that another sulfonylurea drug glipizide also inhibited Sur1 containing K ATP channels but failed to inhibit NLRP3 inflammasome activation."
28740332
reach
"The sulfonylurea drug glyburide, usually used clinically to treat type II diabetes, is a non selective antagonist of NALP3 and could prevent activation of the NALP3 inflammasome and crystal induced IL-1beta secretion."
30186184
reach
"Glyburide (glibenclamide), a sulfonylurea drug used for the treatment of type-2 diabetes, is known to inhibit ATP sensitive K + channels and can thus prevent NLRP3 inflammasome activation."
26279628
reach
"reported that thiazolo-alkenyl sulfonylurea derivative 7 inhibited the activation of NLRP3 by inhibiting ASC oligomerisation ."
34053242
reach
"Likewise, a sulfonylurea drug Glyburide which is widely used for the treatment of Diabetes type 2, was also shown to inhibit the NLRP3 inflammasome."
32574259
reach
"Glyburide (International Nonproprietary Name : glibenclamide), an antidiabetic sulfonylurea drug, inhibits NLRP3 inflammasome activation by several stimuli, without affecting the NLRC4 or NLRP1 inflammasomes [XREF_BIBR]."
25152324
reach
"Glyburide, a sulfonylurea, is reported to inhibit the activation of NLRP3 inflammation by blocking the ATP-sensitive K+ channels (KATP)[61]."
34754842
reach
"The sulfonylurea Glyburide inhibits ATP sensitive K + (K ATP) channels and has been shown to inhibit NLRP3 inflammasome activation, without affecting the NLRP1 or NLRC4 inflammasomes."
26024799
reach
"Compounds with a sulfonylurea fragment can specifically inhibit the activation of the NLRP3 inflammasome in the activation phase without affecting the priming stage dependent on NF-κB signaling [83]."
| PMC
reach
"Moreover, the present study identified the sulfonylurea MCC950 inhibitor of the NLRP3 inflammasome as a promising therapeutic drug for the treatment of VCP associated myopathy."
27730320
reach
"Glibenclamide (GBC), a sulfonylurea drug used for diabetes, has been shown to inhibit the NLRP3 inflammasome pathway, suppress microglia and astrocyte activation, and support favorable neurologic outcomes following rodent CA (93)."
34084772
reach
"Finally, we treated monocytes and MDC with 100 muM glibenclamide, a sulfonylurea drug which inhibits NLRP3 activation but not NLRC4 activation [XREF_BIBR]."
28081233
reach
"The results confirm that the NLRP3 inflammasome and local IL-1beta (+) F4/80 (+) Ly6C (+) macrophages as novel players in the pathogenesis of VCP associated myopathy and identified the sulfonylurea MCC950 inhibitor of the NLRP3 inflammasome with promising therapeutic potential for the treatment of VCP associated myopathy."
27730320
reach
"Furthermore, inhibition of NLRP3 inflammasome by glybenclamide, a sulfonylurea inhibitor of NLRP3 inflammasome, was found to be able to suppress microglial proinflammatory activation and nuclear factor-kappaB activation induced by paraquat and maneb."
32375810